<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>AIMS/HYPOTHESIS: <z:mp ids='MP_0001845'>Inflammation</z:mp> is implicated in the development of type 2 <z:mp ids='MP_0002055'>diabetes</z:mp> and CHD, but the trigger of <z:mp ids='MP_0001845'>inflammation</z:mp> is unclear </plain></SENT>
<SENT sid="1" pm="."><plain>Although in vitro and animal studies support a role of elevated levels of atherosclerotic <z:chebi fb="2" ids="6495">lipoproteins</z:chebi> in the activation of <z:mp ids='MP_0001845'>inflammation</z:mp>, plasma cholesterol cannot predict inflammatory markers in humans </plain></SENT>
<SENT sid="2" pm="."><plain>Moreover, the association between inflammatory markers and other traditional risk factors of <z:mp ids='MP_0002055'>diabetes</z:mp> and CHD is unclear </plain></SENT>
<SENT sid="3" pm="."><plain>To increase our knowledge of in vivo regulation of <z:mp ids='MP_0001845'>inflammation</z:mp>, we examined the association between several traditional risk factors and inflammatory markers </plain></SENT>
<SENT sid="4" pm="."><plain>We hypothesised that because <z:chebi fb="0" ids="39015">apolipoprotein</z:chebi> B (ApoB) reflects atherogenic particle number, it is the primary predictor of inflammatory status </plain></SENT>
<SENT sid="5" pm="."><plain>SUBJECTS, MATERIALS AND METHODS: We examined the association between several traditional risk factors and plasma high-sensitivity (hs) C-reactive protein (CRP), hsTNF-alpha, soluble TNF receptor 1, IL-6, orosomucoid, haptoglobin and alpha(1)-antitrypsin in 77 non-diabetic overweight and <z:mp ids='MP_0001261'>obese</z:mp> postmenopausal women </plain></SENT>
<SENT sid="6" pm="."><plain>RESULTS: The inflammatory markers correlated positively with total and abdominal <z:e sem="disease" ids="C0028754" disease_type="Disease or Syndrome" abbrv="">adiposity</z:e>, blood pressure, 2-h OGTT <z:chebi fb="105" ids="17234">glucose</z:chebi>, <z:hpo ids='HP_0000855'>insulin resistance</z:hpo>, <z:chebi fb="0" ids="17855">triglyceride</z:chebi>, total/<z:chebi fb="4" ids="47775">HDL cholesterol</z:chebi>, ApoB, ApoB:<z:chebi fb="0" ids="39015">apolipoprotein</z:chebi> A1 (ApoA1) ratio and Framingham CHD risk points </plain></SENT>
<SENT sid="7" pm="."><plain>They correlated negatively with ApoA1, and total, <z:chebi fb="15" ids="39026">LDL</z:chebi> and <z:chebi fb="4" ids="47775">HDL cholesterol</z:chebi> </plain></SENT>
<SENT sid="8" pm="."><plain>ApoB was an independent predictor of the interindividual variation in IL-6, hsCRP, orosomucoid, haptoglobin and alpha(1)-antitrypsin (R (2) range 8-40%); other risk factors were less predictive </plain></SENT>
<SENT sid="9" pm="."><plain>Compared with BMI-matched control subjects, women with <z:e sem="disease" ids="C1704417" disease_type="Disease or Syndrome" abbrv="">hyperapobetalipoproteinaemia</z:e> (hyperapoB) had higher hsTNF-alpha, IL-6, hsCRP and orosomucoid (increase 17-104%) </plain></SENT>
<SENT sid="10" pm="."><plain>CONCLUSIONS/INTERPRETATION: ApoB is the primary predictor of inflammatory markers in postmenopausal overweight and <z:mp ids='MP_0001261'>obese</z:mp> women </plain></SENT>
<SENT sid="11" pm="."><plain>Given elevated levels of inflammatory markers in hyperapoB women, we hypothesise that hyperapoB women may have an increased risk of developing both CHD and <z:mp ids='MP_0002055'>diabetes</z:mp> </plain></SENT>
</text></document>